Press & News

ViewReleaseInStandardHtml

Boule´s proprietary technology at the core of the new platform. Intangible assets are written down by SEK 40 million.

The development of the next generation product platform has now reached a defining milestone regarding design, specification and choice of core technology. During the development process, different solutions were evaluated, one of which included the acquisition of laser optics technology. However, as a consequence of other considerations and choice of technology, a different development path has proven to yield better results why the acquired technology and associated investments are written down by SEK 40 million. The write-downs will impact the fourth quarter earnings of 2020 but will have no effect on cash flow.

“I am very pleased that we have concluded all essential technology choices for our new product platform. The past year's strengthening of the organization has enabled the development of this new technical solution, which meets our high demands and becomes a stable basis for our continued development work. Our team has done a fantastic job, even if the impact on our income statement is, of course, regrettable", says Boule Diagnostics CEO Jesper Söderqvist.

Helena Börjesson, CTO at Boule comments: "We have paved a clear and stable way towards the first release, an advanced 5-part instrument for the human market, and we look forward with confidence to the industrialization phase we are now embarking on."

An advanced 5-part instrument for the human market, based on the new platform, is planned to be launched at the end of 2022.

About Boule’s new platform

  • The first release on the new platform will be an advanced 5-part human diagnostics instrument.
  • Over time, Boule's current offering will be supplemented and replaced with products based on the new platform.
  • The new platform combines impedance and laser technology to be able to measure more parameters regarding blood cells.
  • The market for near-patient diagnostics is the largest for 3-part instruments, but the market for 5-part instruments is growing faster.

For further information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone. +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone. +46 (0)70-546 72 22

 

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com

 

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 17:00 CET on December 22, 2020.